BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 22527424)

  • 1. Treatment of actinic keratoses with 5% topical imiquimod: a multicenter prospective observational study from 93 Austrian office-based dermatologists.
    Strohal R; Kerl H; Schuster L
    J Drugs Dermatol; 2012 May; 11(5):574-8. PubMed ID: 22527424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses.
    Quist SR; Gollnick HP
    Expert Opin Pharmacother; 2011 Feb; 12(3):451-61. PubMed ID: 21254950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
    Shaffelburg M
    J Drugs Dermatol; 2009 Jan; 8(1):35-9. PubMed ID: 19180894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.
    Swanson N; Abramovits W; Berman B; Kulp J; Rigel DS; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):582-90. PubMed ID: 20133013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.
    Hanke CW; Beer KR; Stockfleth E; Wu J; Rosen T; Levy S
    J Am Acad Dermatol; 2010 Apr; 62(4):573-81. PubMed ID: 20133012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Imiquimod 3.75% from Lmax in Actinic Keratosis According to Fitzpatrick Skin Type.
    Alomar A; Stockfleth E; Dirschka T; Gupta G; Aractingi S; Dakovic R; Peris K
    J Drugs Dermatol; 2016 Mar; 15(3):285-9. PubMed ID: 26954313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams.
    Price NM
    J Drugs Dermatol; 2007 Aug; 6(8):778-81. PubMed ID: 17763606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the clinical and histopathological classifications of actinic keratosis and the efficacy of topical imiquimod treatment.
    Yu A; Tanizaki H; Kokunai Y; Kaneda K; Sugimoto A; Otsuka T; Kurokawa T; Moriwaki S
    J Dermatol; 2018 Apr; 45(4):496-500. PubMed ID: 29265412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
    Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream.
    Torres A; Storey L; Anders M; Miller RL; Bulbulian BJ; Jin J; Raghavan S; Lee J; Slade HB; Birmachu W
    J Transl Med; 2007 Jan; 5():7. PubMed ID: 17257431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study for the effect of photodynamic therapy, imiquimod immunotherapy and combination of both therapies on 40 lesions of actinic keratosis in Japanese patients.
    Tanaka N; Ohata C; Ishii N; Imamura K; Ueda A; Furumura M; Yasumoto S; Kawakami T; Tsuruta D; Hashimoto T
    J Dermatol; 2013 Dec; 40(12):962-7. PubMed ID: 24147543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
    Gebauer K; Shumack S; Cowen PS
    Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective combination of photodynamic therapy and imiquimod 5% cream in the treatment of actinic keratoses: three cases.
    Held L; Eigentler TK; Leiter U; Garbe C; Berneburg MJ
    Biomed Res Int; 2013; 2013():102698. PubMed ID: 23484071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.
    Oyama S; Funasaka Y; Tsuchiya SI; Kawana S; Saeki H
    J Dermatol; 2017 Aug; 44(8):944-949. PubMed ID: 28342266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multiple, multiform actinic keratoses on the head with imiquimod 5% cream.
    Stockfleth E; Ulrich C; Lange-Asschenfeldt B; Kremer HJ; Drecoll U; Maus J; Röwert-Huber J
    Eur J Dermatol; 2009; 19(4):355-9. PubMed ID: 19467962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imiquimod cream in the treatment of actinic keratoses.
    Persaud A; Lebwohl M
    J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S236-9. PubMed ID: 12271285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.
    Gupta G; Stockfleth E; Peris K; Aractingi S; Alomar A; Dakovic R; Dirschka T
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1840-2. PubMed ID: 25174261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate.
    Serra-Guillen C; Nagore E; Hueso L; Llombart B; Requena C; Sanmartín O; Botella-Estrada R; Guillen C
    Br J Dermatol; 2011 Feb; 164(2):429-33. PubMed ID: 20973770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.